Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Pharm Res. 2015 Mar 4;32(8):2753–2763. doi: 10.1007/s11095-015-1660-z

Table II.

Platinum plasma pharmacokinetic parameters after intraperitoneal (IP) or intravenous (IV) administration of nanoemulsion (NE) formulations and cisplatin in nu/nu mice, (n=3).

Group Route t1/2 (h) Tmax (h) Cmax (μg/mL) Vd (mL/kg) Cl (mL/h/kg) MRT (h) AUClast (h*μg/mL)
Non-targeted NE IP 11 3.0 5.4 1021 63 15 63
EGFR-targeted NE IP 15 3.0 7.3 889 41 22 81
Non-targeted NE IV 12 0.08 25 804 46 16 82
EGFR-targeted NE IV 10 0.5 20 657 45 14 86
Cisplatin (Total – Bound and Unbound) IV 9.6 0.083 6.9 6,752 485 18.6 14
Cisplatin (Unbound) IV 2.8 0.083 2.6 31,278 7,776 1.7 1.2